Myeloma

HAEM-MYEL-009 Lenalidomide +/- dexamethasone v2

HAEM-MYEL-031 Cyclophosphamide, Lenalidomide and Dexamethasone v4

HAEM-MYEL-032 MPV v2

HAEM-MYEL-033 Carfilzomib for multiple myeloma v3

HAEM-MYEL-035 Ixazomib with Lenalidomide and Dexamethasone v4

HAEM-MYEL 036 Daratumumab IV v4

HAEM-MYEL-037 Daratumumab IV in combination with bortezomib and dexamethasone v5

HAEM-MYEL-038 Daratumumab IV in combination with bortezomib and dexamethasone (weekly) v5

HAEM-MYEL-039 Isatuximab, pomalidomide and dexamethasone v2

HAEM-MYEL-040 Daratumumab SC v2

HAEM-MYEL-041 Daratumumab SC in combination with bortezomib (D1, 4, 8 & 11) and dexamethasone v3

HAEM-MYEL-042 Daratumumab SC in combination with bortezomib and dexamethasone (weekly) v3

HAEM-MYEL-043 Panobinostat, Bortezomib (SC) Dexamethasone (28 day cycle) v1

HAEM-MYEL-044 Lenalidomide maintenance v2

HAEM-MYEL-045 Carfilzomib, lenalidomide and dexamethasone v4

HAEM-MYEL-046 Daratumumab (SC) with bortezomib, thalidomide and dexamethasone v1

HAEM-MYEL-047 Daratumumab (SC) with bortezomib (weekly), thalidomide and dexamethasone v1

HAEM-MYEL-048 Daratumumab (SC) with lenalidomide and dexamethasone v1

Links for Prescription Authorisation Forms

Revlimid

Thalidomide Celgene